MissionIR Articles

Cardium Therapeutics has built a name for itself by capturing innovative biomedical technologies that emerge in the health sciences and regenerative medicine space, while simultaneously developing its own technology portfolio. By focusing on underserved demand…

In recent months the Biotech Industry has become a hotbed of Merger and Acquisition (M&A) activity and speculation. As large pharmaceuticals face major patent expirations in 2012 they have looked to biotech companies to provide…

Cardium Therapeutics is currently exhibiting its new FDA-cleared Excellagen® professional-use, syringe-based wound care product for the management of diabetic foot ulcers, pressure ulcers and other dermal wounds at the 2012 Spring Symposium on Advanced Wound…

Smith Medical Partners, the specialty pharmaceutical subsidiary of H. D. Smith, today announced an exclusive logistics and cold chain services agreement with Cardium Therapeutics, a health sciences and regenerative medicine company, to support its recently…

Friday, Cardium Therapeutics announced Excellagen’s introduction into U.S. markets. Excellagen is a wound care product for dermal wounds, such as diabetic foot ulcers and other types of pressure ulcers. Cardium is focused on the acquisition…

Cardium Therapeutics today presented highlights of financial results for its fourth quarter and fiscal year ended December 31, 2011, and other recent developments and outlook for 2012. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) Highlights of 2011 and Recent Developments Initiated market…

Cardium Therapeutics today announced market introduction of its Excellagen™ professional-use, syringe-based wound care product for the management of diabetic foot ulcers, pressure ulcers and other dermal wounds. (Photo:  http://photos.prnewswire.com/prnh/20120330/LA79308) (Logo:  http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) Excellagen is a new,…

Nutritional Products International (NPI) and Cardium Therapeutics today announced that MedPodium Nutra-Apps® products are now available on RevNutrition.com. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) The MedPodium Nutra-Apps brand offers easy-to-use dietary supplements that have been formulated to promote personal…

Cardium Therapeutics today announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of Cardium’s lead product candidate, Generx® (Ad5FGF-4) in patients with myocardial ischemia (insufficient blood flow in the…

Cardium Therapeutics  is now making its MedPodium Nutra-Apps® products available across the United States by working with Nutritional Products International (NPI) and InHealth Media. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) Nutra-Apps are easy-to-use dietary supplements designed to promote personal…

Biotechnology stocks have performed well of late as companies from across the globe earn more investments. According to a report from Boulder-based data company OnBioVC, biotech companies attracted close to double the amount of investment…

Cardium Therapeutics today announced that it has completed the previously announced sale of 17,857,143 shares of its common stock in a registered direct offering for gross proceeds of approximately $5.0 million, before deducting placement agent’s…

Cardium Therapeutics today announced that it has entered into definitive agreements with three institutional and accredited investors to sell an aggregate of 17,857,143 shares of its common stock in a registered direct offering for gross…

Cardium Therapeutics today reported on new insights and confirmatory preclinical study results on the Generx (Ad5FGF-4) angiogenic therapy product candidate based on the Company’s sponsored research conducted at Emory University.  The findings, which provide further…

Biotechnology stocks have been on fire of late. The iShares Biotechnology index is up more than 12 percent over the last month as investors brace for big drug launches, FDA hearings, and greater M&A activity…

Cardium Therapeutics today reported that it had received notice from NYSE Regulation that the Company is now considered to have regained compliance with the listing requirements of the NYSE Amex LLC (formerly the American Stock…

Cardium Therapeutics today announced that it has entered into its first international agreement for the commercialization of Excellagen™ in the South Korean market. Cardium entered into a marketing and distribution agreement with BL&H Co. Ltd.,…

Cardium Therapeutics today announced that it is scheduled to present at the Biotech Showcase 2012 and the 5th Annual OneMedForum Conference in San Francisco. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) The 2012 Biotech Showcase is being held at the…

Cardium Therapeutics Inc. today reported on its exchange listing compliance with NYSE Amex LLC (formerly the American Stock Exchange). The Company reports that its estimated stockholders’ equity is now in excess of the threshold requirements…

Cardium Therapeutics Inc. today announced that it has entered into a cross-strategic investment agreement with SourceOne Global Partners, a leading supplier of exclusive science-based ingredients and proprietary formulas to the nutritional supplement and related functional…